Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Glenmark Pharmaceuticals

Evaluate

February 07, 2023

Nimbus hopes to strike thrice

But the group has chosen the tough immuno-oncology space for its third attempt to woo the big players.

Thumbnail
August 26, 2022

Drug makers leave the pain behind

Developing non-opioid analgesics remains one of the hardest tasks in biopharma.

Article image
Vantage logo
April 26, 2022

Late-stage pain pipeline refuses to swell

Setbacks from Eliem, Ampio and Acadia thin an already sparse pain pipeline, which remains lacking in serious interest from big developers.

Article image
Vantage logo
February 01, 2022

US FDA approval tracker: January 2022

Article image
Vantage logo
January 11, 2021

Sanofi makes a pre-JP Morgan splash with Kymab

The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.

Article image
Vantage logo
February 28, 2019

Go or no go? Johnson & Johnson awaits Spravato nod

Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.

Article image
Vantage logo
December 17, 2018

Lilly buys into ion channels – again

Vantage logo
December 15, 2016

Eucrisa thumbs up validates Pfizer’s takeover strategy – partly

Vantage logo
September 02, 2016

Behold the son of Blincyto

Vantage logo
July 16, 2013

Early-stage asset risk no deterent to partnering deals

Vantage logo
January 02, 2013

Pharma regulatory news over the Christmas period

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up